Market Overview

GSK, Theravance Report Results From the SUMMIT COPD CV Survival Study; Primary Endpoint Not Statistically Significant

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: News FDA

 

Related Articles (THRX + GSK)